{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/parvovirus-b19-infection/background-information/complications/","result":{"pageContext":{"chapter":{"id":"1cfa61b6-71af-5e94-9e40-95b29e9f97dc","slug":"complications","fullItemName":"Complications","depth":2,"htmlHeader":"<!-- begin field 0a022d5f-c5e0-43e9-a745-39acbca33167 --><h2>What are the complications?</h2><!-- end field 0a022d5f-c5e0-43e9-a745-39acbca33167 -->","summary":"","htmlStringContent":"<!-- begin item 554641da-c0bd-4038-bc04-e2ad1b93809c --><!-- begin field 13ef2d25-24c2-4814-a932-e0db66007780 --><p><strong>Complications of parvovirus B19 infection are rare in healthy children and adults. Pregnant women, and people who are immunocompromised or have haematological disorders such as hereditary anaemias, are at increased risk of serious and potentially life-threatening complications.</strong></p><ul><li><strong>Pregnancy</strong><ul><li>Non-immune hydrops fetalis<ul><li>Infection of fetal erythroid progenitor cells in the bone marrow and liver may cause profound anaemia, hypoalbuminaemia, heart failure, and hydrops fetalis (defined as subcutaneous oedema in at least two fetal compartments). There may be associated hepatitis and myocarditis in the fetus.</li><li>The average time between onset of maternal infection and fetal symptoms is 6 weeks, but may be months.</li><li>This may cause fetal loss in about 50% of cases, if untreated.</li></ul></li><li>Fetal death<ul><li>This may occur spontaneously or as a consequence of hydrops fetalis.</li><li>Infection in the first 20 weeks of pregnancy increases the risk.</li><li>The overall fetal loss rate for those with maternal infection is 5–10%.</li><li>Fetal loss usually occurs in the second trimester, and is rare in the first trimester.</li></ul></li><li>Maternal pre-eclampsia-like syndrome ('mirror syndrome').<ul><li>This is rare, and typically presents in late pregnancy with clinical features of maternal peripheral oedema, hypertension, proteinuria, and anaemia during conservative management of hydrops fetalis.</li><li>It is so-called because the maternal signs reflect those present in the fetus.</li></ul></li><li>Note: universal screening of pregnant women for past parvovirus B19 infection is not recommended, as there is no vaccine or prophylaxis treatment available.</li></ul></li><li><strong>People who are immunocompromised (for example leukaemia, lymphoma, HIV infection, receiving chemotherapy, or bone marrow or solid organ transplantation) or have a haematological disorder (for example sickle cell disease, thalassaemia, hereditary spherocytosis, or autoimmune haemolytic anaemia):</strong><ul><li>Transient aplastic anaemia<ul><li>People with an underlying haemolytic disorder or who have increased red blood cell turnover are more at risk.</li><li>This usually causes a severe, transient anaemia which is self-limiting, however potentially life-threatening aplastic crisis may occur when there is severe anaemia associated with no reticulocyte production (which may cause angina, heart failure, and bone marrow necrosis).</li><li>Affected people may initially present with severe anaemia associated with pallor, weakness, lethargy, fever, tachycardia, and tachypnoea.</li></ul></li><li>Pure red cell aplasia<ul><li>People who are immunocompromised are more at risk.</li><li>Persistent parvovirus B19 infection may cause chronic bone marrow suppression with chronic, severe, or recurrent anaemia and potential life-threatening pancytopenias.</li></ul></li><li>Neurological complications<ul><li>These include encephalitis, meningitis, stroke disease, and peripheral neuropathy.</li></ul></li><li>Other complications (rare)<ul><li>These include myocarditis, nephritic syndrome, hepatitis, and vasculitis.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">American Association of Blood Banks, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">HPA, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">Lamont, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">Slavov, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">MacMahon, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">Desilets, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">O&#39;Grady, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">UK National Screening Committee, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">SOGC, 2014</a>]</p><!-- end field 13ef2d25-24c2-4814-a932-e0db66007780 --><!-- end item 554641da-c0bd-4038-bc04-e2ad1b93809c -->","topic":{"id":"a0e6adce-f85f-55b0-8d7f-3b5e75836d40","topicId":"3ea4cf87-3eee-4e3f-a6d0-b0ee3a4ee3ad","topicName":"Parvovirus B19 infection","slug":"parvovirus-b19-infection","lastRevised":"Last revised in February 2017","chapters":[{"id":"c45face5-dc30-586a-b7ca-3b24305bd068","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"cc09231e-bb7a-5379-aeec-7c830288098e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2971cfc1-4839-5be6-b726-20b9383ae294","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"020d2cdb-0f7f-5bc0-a249-98fc3690b68c","slug":"changes","fullItemName":"Changes"},{"id":"af1bc49c-d614-521b-b6f3-ad084fc2aed9","slug":"update","fullItemName":"Update"}]},{"id":"7c9f0c10-cf1d-5723-856f-e0bc2d270210","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bb1635ce-433b-5f39-a93a-27b4488878c5","slug":"goals","fullItemName":"Goals"},{"id":"3c7eed51-287a-5bcb-8519-40ef7f5784aa","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"291f85a1-8911-59d4-82d6-62ce4daff1c0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e66b8854-eb00-59b9-85d9-f50343f36470","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ce817770-4fbe-5b47-b4ed-56b723012488","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"faa5c5db-5837-5cbd-8e56-78bc7ac42137","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0f0e8f26-e2c7-5de3-b012-e340b25ad622","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"afcf1b63-41ac-5295-91b5-4e19bc828249","slug":"definition","fullItemName":"Definition"},{"id":"60a93741-3863-58bb-8394-a33804062373","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1cfa61b6-71af-5e94-9e40-95b29e9f97dc","slug":"complications","fullItemName":"Complications"},{"id":"034c66fb-a99f-5a21-a031-d557dc647301","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"53019719-ec11-57d5-afd3-3ed2e9939168","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e7eca192-b219-5e71-8ecd-6d2e6cf0f3da","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"2b824d0f-b0b0-5801-8def-a38d172c2532","slug":"investigations","fullItemName":"Investigations"},{"id":"7daba43a-1410-5703-8a94-b6530a5dfccc","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"b0275eae-f19c-57fb-834c-03df7c6dcea3","fullItemName":"Management","slug":"management","subChapters":[{"id":"73c2e9d4-b567-504f-9b28-36966a247590","slug":"children-adults-not-pregnant","fullItemName":"Scenario: Children and adults (not pregnant)"},{"id":"25b4fecb-ae9d-58f7-ad14-7ace595c0800","slug":"pregnant-women","fullItemName":"Scenario: Pregnant women"}]},{"id":"bdf3d270-5563-5eb4-804f-68fce2e7e7dd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"73875656-8429-5584-82e6-d06c0a5f52ea","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8dc117ba-c373-5ee0-a7aa-fc63a62a7067","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"24bd5691-28ce-53b1-be8b-f0e51e40db4b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6b35b969-66a8-5431-900a-a524f0bf1a89","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"63ad51a8-8325-52f2-a254-ed3ccae9f508","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"174a35a7-6fa3-58ef-9e06-6325d5f0111b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c6c0fc6f-31f8-5681-bbce-4ed5b6b16e4e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0f0e8f26-e2c7-5de3-b012-e340b25ad622","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}